Skip to main content
OpenTrials
Completed

NCT Number: NCT04911062

HTX-011 in Spinal Surgery

This is a Phase 2, multicenter study in subjects undergoing an open lumbar decompression surgery.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Arizona Research Center, Phoenix, Arizona, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Is scheduled to undergo an open 1-3 level lumbar decompression surgery with or without fixation under general anesthesia.
  • Females are eligible only if not pregnant, not lactating, not planning to become pregnant during the study.

Exclusion criteria

  • Has a contraindication of a known or suspected history of hypersensitivity or clinically significant idiosyncratic reaction to required study medications.
  • Has a history of severe allergic reaction due to aspirin or other NSAIDs, or known history of severe gastrointestinal adverse reactions associated with NSAID use.
  • Has functioning intrathecal drug pump or spinal cord stimulator.
  • Opioid use for most days within the last 3 months.
  • Has initiated treatment with selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs), gabapentin, pregabalin, or duloxetine within 1 month prior to the scheduled surgery.
  • Received an investigational product or device in a clinical trial within 30 days or within 5 elimination half-lives.
  • Has a history of clinically significant cardiac abnormality, coronary artery bypass graft surgery within 12 months, or suspected coagulopathy or uncontrolled anticoagulation.
  • Has impaired balance and is at risk of falling.
  • Is currently undergoing treatment for hepatitis B, hepatitis C, or HIV.
  • Has undergone 3 or more surgeries within 12 months.
  • Has a known history of glucose-6-phosphate dehydrogenase deficiency.
  • Has History of liver cirrhosis, having an aspartate aminotransferase >3 × the upper limit of normal (ULN), or having an alanine aminotransferase >3 × ULN.

Treatment and study plan

Bupivacaine HCI without epinephrine

Drug

100 mg administered via injection into the surgical site.

HTX-011

Drug

HTX-011 (bupivacaine/meloxicam) dose up to 200 mg/6 mg administered via application into the surgical site.

Luer Lock Applicator

Device

Applicator for instillation.

Primary outcomes

  1. Incidence of Serious Adverse Events

    Time frame: From the time the subject signs the ICF through the Day 29 Visit

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    Time frame: Baseline through 120 hours

  2. Time of occurrence of maximum concentration (Tmax)

    Time frame: Baseline through 120 hours

  3. Area under the concentration-time curve from Time 0 to the time of last quantitative concentration (AUClast)

    Time frame: Baseline through 120 hours

  4. Area under the concentration-time curve from Time 0 extrapolated to infinity (AUCinf)

    Time frame: Baseline through 120 hours

  5. Apparent terminal half-life (t½)

    Time frame: Baseline through 120 hours

Sponsors and collaborators

Lead sponsor

Heron Therapeutics

Industry

Registry information

Official study title

A Phase 2, Two-Part, Multicenter Study of HTX-011 in Spinal Surgery

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Jun 2, 2021
Registry last updated
Jun 12, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.